Review of vorapaxar for the prevention of atherothrombotic events

Vorapaxar in Patients With Diabetes Mellitus and Previous Myocardial Infarction: Findings From the Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events-TIMI 50 Trial

(2015) M. A. Cavender et al.   CIRCULATION

Platelet transfusion reverses bleeding evoked by triple anti-platelet therapy including vorapaxar, a novel platelet thrombin receptor antagonist

(2015) Tian-Quan Cai et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Efficacy and Safety of Vorapaxar as Approved for Clinical Use in the United States

(2015) G. Magnani et al.   Journal of the American Heart Association

Vorapaxar in patients with peripheral artery disease and acute coronary syndrome: Insights from Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER)

(2014) William Schuyler Jones et al.   AMERICAN HEART JOURNAL

Usefulness and Safety of Vorapaxar in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention (from the TRACER Trial)

(2014) Marco Valgimigli et al.   AMERICAN JOURNAL OF CARDIOLOGY

Coronary Stent Thrombosis With Vorapaxar Versus Placebo

(2014) Marc P. Bonaca et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes

(2014) Ezra A. Amsterdam et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Vorapaxar in Patients With Peripheral Artery Disease

(2013) Marc P. Bonaca et al.   CIRCULATION

Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA{middle dot}CER) trial

(2013) S. Leonardi et al.   EUROPEAN HEART JOURNAL

The Effect of Multiple Doses of Ketoconazole or Rifampin on the Single- and Multiple-Dose Pharmacokinetics of Vorapaxar

(2013) Teddy Kosoglou et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Management of Patients With Peripheral Artery Disease (Compilation of 2005 and 2011 ACCF/AHA Guideline Recommendations)

(2013) Jeffrey L. Anderson et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Vorapaxar in Acute Coronary Syndrome Patients Undergoing Coronary Artery Bypass Graft Surgery

(2013) David J. Whellan et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Efficacy and Safety of Vorapaxar in Patients With Prior Ischemic Stroke

(2013) David A. Morrow et al.   STROKE

Pharmacokinetics of the novel PAR-1 antagonist vorapaxar in patients with hepatic impairment

(2012) Paul Statkevich et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Pharmacokinetics and pharmacodynamics of the novel PAR-1 antagonist vorapaxar in patients with end-stage renal disease

(2012) Teddy Kosoglou et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial

(2012) Benjamin M Scirica et al.   LANCET

Vorapaxar in the Secondary Prevention of Atherothrombotic Events

(2012) David A. Morrow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pharmacodynamics and pharmacokinetics of the novel PAR-1 antagonist vorapaxar (formerly SCH 530348) in healthy subjects

(2011) Teddy Kosoglou et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes

(2011) Pierluigi Tricoci et al.   NEW ENGLAND JOURNAL OF MEDICINE

Identification of Human Liver Cytochrome P450 Enzymes Involved in the Metabolism of SCH 530348 (Vorapaxar), a Potent Oral Thrombin Protease-Activated Receptor 1 Antagonist

(2010) A. Ghosal et al.   DRUG METABOLISM AND DISPOSITION

Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes

(2009) Lars Wallentin et al.   NEW ENGLAND JOURNAL OF MEDICINE